{"filings":[{"id":1645884,"accession_number":"0001728117-26-000061","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-07-15T00:39:46+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Gossamer Bio stockholders approve 4B authorized shares, new incentive plan, and note/warrant issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved charter amendment increasing authorized common shares from 700M to 4B.","Stockholders approved restated 2019 Incentive Award Plan to increase shares available for issuance.","Stockholders approved potential issuance of shares upon conversion of up to $72M in new 7.50% Convertible Senior Secured First Lien Notes due 2030 and exercise of 135.8M purchase warrants.","Exchange offer for $200M 5.00% Convertible Senior Notes due 2027 closed on June 4, 2026, with new notes and warrants issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1370716,"accession_number":"0001728117-26-000057","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-07-01T13:01:08+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gossamer Bio sets conversion price ~$0.19/sh for 7.50% notes; warrant strike $0.34","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial conversion rate: 5,347.5936 shares per $1,000 principal of 2030 Convertible Notes, equivalent to ~$0.19 conversion price.","Initial exercise price for Purchase Warrants set at $0.34 per share of common stock.","Reference price of $0.17 determined over seven trading days starting June 22, 2026, used to calculate both prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1093519,"accession_number":"0001728117-26-000054","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-06-17T12:01:14+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gossamer Bio completes exchange of 94.5% of 2027 notes; $18.9M remain outstanding","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$181.1M principal (94.5%) of 5% 2027 notes tendered; exchanged for new 7.5% 2030 notes and equity.","Company lowered tender condition from 98% to 90.5% after sufficient early participation by June 2.","Early settlement occurred June 4; supplemental indenture eliminated restrictive covenants.","No additional notes tendered after early date; $18.9M of existing notes remain outstanding.","New 7.5% secured first lien notes due 2030, plus up to 317.6M shares or prefunded warrants issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":869721,"accession_number":"0001728117-26-000045","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-06-04T23:28:31+00:00","items":["1.01","1.02","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Gossamer Bio exchanges 90.5% of 5% notes for new 7.5% notes, stock, and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$181M of 5% Convertible Senior Notes due 2027 tendered and cancelled (90.5% of outstanding).","Issued $65M of new 7.5% Convertible Senior Secured First Lien Notes due 2030.","Issued 254M common shares, 33.4M prefunded warrants, and 135.8M purchase warrants.","Remaining $18.9M of existing notes outstanding; exchange offer open until June 16, 2026.","Consent solicitation adopted amendments eliminating restrictive covenants in existing indenture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":869728,"accession_number":"0001728117-26-000042","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-06-04T21:34:07+00:00","items":["5.07"],"status":"ready","headline":"Gossamer Bio shareholders re-elect directors, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Faheem Hasnain re-elected as Class II director with 92.3M for, 26.7M withheld, 45.5M broker non-votes.","Russell Cox re-elected as Class II director with 89.0M for, 30.0M withheld, 45.5M broker non-votes.","Ratification of Ernst & Young as auditor for FY2026 passed: 163.2M for, 1.2M against, 41K abstain.","Advisory vote on named executive officer compensation approved: 111.3M for, 7.5M against, 137K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787917,"accession_number":"0001728117-26-000040","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-06-02T12:00:32+00:00","items":["8.01","9.01"],"status":"ready","headline":"Gossamer Bio extends early tender deadline for exchange offer; $181M of notes tendered","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Early tender deadline extended to 5:00 p.m. ET on June 2, 2026; early settlement expected June 4, 2026.","$181,052,000 in aggregate principal of 5.00% Convertible Senior Notes due 2027 validly tendered as of June 1.","Exchange offer requires minimum 98% of aggregate principal to be tendered; withdrawal deadline expired June 1.","New 7.50% Convertible Senior Secured First Lien Notes due 2030 offered, up to $72.0M principal.","Up to 317,647,058 shares of common stock (or prefunded warrants) offered as part of exchange consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":481996,"accession_number":"0001728117-26-000036","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-05-18T11:06:58+00:00","items":["1.01","2.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Gossamer Bio launches exchange offer for 5.00% notes; holders of 75.2% support","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchange Offer: up to $72M new 7.50% Convertible Secured Notes due 2030, plus up to 317.6M common shares and 150M Purchase Warrants.","Supporting Noteholders holding 75.2% of existing notes agree to tender and consent to indenture amendments.","Conditions include minimum 98% participation; early settlement expected June 3, final June 18, 2026.","Also filed Q1 2026 financial results (press release not provided in filing text).","Stockholder proposals include increasing authorized shares from 700M to 4B and reverse stock split (1:10 to 1:150)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95038,"accession_number":"0001728117-26-000022","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Gossamer Bio receives Nasdaq bid price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Gossamer on April 8, 2026 that stock bid price <$1.00 for 30 consecutive business days (Feb 24 – Apr 7, 2026).","Company has 180 calendar days, until Oct 5, 2026, to regain compliance by closing bid >=$1.00 for 10 consecutive business days.","If not cured by Oct 5, may transfer to Nasdaq Capital Market for additional 180-day compliance period if eligible.","Company will monitor price and consider options including reverse stock split if needed.","No assurance of regaining compliance; potential delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107824,"accession_number":"0001728117-26-000018","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio reports 2025 net loss $170.4M; seralutinib Phase 3 narrowly missed primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PROSERA Phase 3 in PAH showed placebo-adjusted 6MWD +13.3 meters but missed prespecified statistical alpha of 0.025 (p=0.0320).","Enrollment in Phase 3 SERANATA (PH-ILD) paused; Company evaluating implications and plans FDA Type C meeting in June 2026.","Implemented reduction in force and cost-containment measures to align resources with near-term priorities.","Cash, equivalents and marketable securities $136.9M at Dec 31, 2025; expected to fund operations into Q1 2027.","Net loss for FY2025 was $170.4M ($0.75 per share) compared to $56.5M ($0.25 per share) in FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107823,"accession_number":"0001728117-26-000004","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Gossamer Bio Phase 3 PROSERA trial misses primary endpoint, seralutinib shows signals in high-risk PAH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary 6MWD endpoint missed: +13.3m placebo-adjusted (p=0.0320 vs prespecified α=0.025).","Four key secondary endpoints favored seralutinib; NT-proBNP reduced 120.4 ng/L (p=0.0002).","In intermediate/high-risk (REVEAL Lite 2 ≥6, n=234), 6MWD gain +20.0m (p=0.0207).","Gossamer to meet with FDA to discuss path forward; pauses SERANATA study enrollment.","Seralutinib well tolerated; cough (37%) and transaminase elevations >3x ULN (13%) reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124220,"accession_number":"0001728117-25-000082","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q3 net loss $48.2M; PROSERA topline due Feb 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $48.2M ($0.21 per share) vs $30.8M loss a year ago; revenue from Chiesi collab $13.3M.","Cash, cash equivalents and marketable securities $180.2M; sufficient to fund ops into 2027.","PROSERA Phase 3 PAH study enrollment complete (390 pts); topline results expected February 2026.","First site activated for SERANATA Phase 3 PH-ILD study; targeting enrollment of ~480 patients.","Strategic option agreement to acquire Respira via 1.5M shares; no new trials expected before 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":34672000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140887,"accession_number":"0001728117-25-000076","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Gossamer Bio issues 2.5M shares for option to acquire Respira Therapeutics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,500,000 shares to Prana Bio on Sept 24, 2025 as consideration for option to acquire Respira via merger.","Option exercisable until Dec 31, 2027 or earlier upon completion of certain Respira development activities.","May issue up to 1.5M additional shares upon exercise, plus up to ~6.7M shares on regulatory and sales milestones.","Shares issued in reliance on Section 4(a)(2) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140886,"accession_number":"0001728117-25-000069","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q2 net loss $38.3M; PROSERA Phase 3 topline due Feb 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.3M ($0.17 per share) vs net income $49.2M in Q2 2024, driven by $88.8M one-time license revenue in prior year.","Cash, equivalents and marketable securities $212.9M as of June 30, 2025; runway into 2027.","PROSERA Phase 3 PAH study enrolled 390 patients; topline results expected February 2026.","SERANATA Phase 3 PH-ILD study first site activations planned Q4 2025; 480-patient, 24-week trial.","Collaboration revenue $11.5M (mostly cost reimbursement from Chiesi) vs $95.8M in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":21378000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158638,"accession_number":"0001728117-25-000043","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Stockholders re-elect three Class I directors, approve amended incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors re-elected: Thomas Daniel, Sandra Milligan, Steven Nathan.","Ratification of Ernst & Young as auditor for FY2025 approved (176.5M for, 98k against).","Advisory vote on named executive officer compensation approved (125.4M for, 3.8M against).","Amended and Restated 2019 Incentive Award Plan approved (87.8M for, 41.5M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158637,"accession_number":"0001728117-25-000040","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Gossamer Bio completes enrollment in Phase 3 PROSERA study for seralutinib in PAH (n=390)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Global registrational Phase 3 PROSERA study fully enrolled; topline results expected February 2026.","Enrolled 390 patients vs 86 in Phase 2; mean 6MWD 374 m (vs 408 m), NT-proBNP 987 ng/L (vs 628).","74% of patients are Functional Class III vs 42% in Phase 2; enrichment criteria applied to target responders.","Study is double-blind, placebo-controlled, primary endpoint change in 6MWD at week 24.","Seralutinib developed with Chiesi Group; positive milestone for first-in-class PAH treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158636,"accession_number":"0001728117-25-000037","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio closes new patient screening in PAH Phase 3 PROSERA study; Q1 net loss $36.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Enrollment of 343 patients completed; to exceed 350 by early June; topline results expected Feb 2026.","Baseline characteristics align with target: mean 6MWD 376 m, 74% Functional Class III, NT-proBNP 986 ng/L.","Phase 3 SERANATA study in PH-ILD to begin site activations in Q4 2025 with ~480 patients.","Cash $257.9M expected to fund operations into H1 2027; Q1 net loss $36.6M ($0.16/share).","Revenue from Chiesi collaboration $9.9M ($6.6M cost reimbursement); R&D expenses $38.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":9889000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177039,"accession_number":"0001728117-25-000022","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q4 2024 net loss $33M; PROSERA Phase 3 topline due Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $294.5M at year-end; runway into H1 2027.","Full-year 2024 net loss $56.5M ($0.25/share) vs $179.8M ($1.18) in 2023.","R&D expenses $138.5M in 2024 vs $135.3M in 2023; G&A $36.1M vs $38.5M.","PROSERA Phase 3 in PAH on track for topline data readout in Q4 2025.","PH-ILD registrational Phase 3 to commence H2 2025; seralutinib got Japan orphan PAH designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177038,"accession_number":"0001728117-25-000004","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gossamer Bio regains Nasdaq minimum bid price compliance; deficiency closed.","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 19, 2025 confirming regained compliance with minimum bid price rule.","Previously notified of deficiency on Sept 11, 2024 for failing to maintain $1.00 bid price for 30 days.","Compliance matter now closed; common stock remains listed on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193808,"accession_number":"0001728117-24-000093","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q3 net loss $30.8M; cash $327M, runway into H1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.8M ($0.14/share) vs $40.0M ($0.21/share) in Q3 2023; revenue from Chiesi collaboration was $9.5M.","Cash, cash equivalents & marketable securities $327M as of Sept 30, 2024; expected to fund operations into H1 2027.","Phase 3 PROSERA trial in PAH enrollment ongoing; topline results expected Q4 2025.","Expect to commence global registrational Phase 3 trial for PH-ILD in mid-2025.","R&D expenses $34.9M (up from $31.2M); G&A $8.5M (down from $9.3M) YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":105322000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210147,"accession_number":"0001728117-24-000088","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Gossamer Bio receives Nasdaq bid-price deficiency notice; deadline March 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Gossamer Bio that its stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Sept 10, 2024.","Company has 180 calendar days, until March 10, 2025, to regain compliance by closing at $1.00 for at least 10 consecutive business days.","If not compliant by March 2025, may transfer to Nasdaq Capital Market for an additional 180-day cure period, subject to other standards.","Company may consider options such as a reverse stock split but cannot guarantee it will regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210146,"accession_number":"0001728117-24-000086","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q2 2024 net income $49.2M; cash $354.5M; Chiesi collaboration on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $49.2M ($0.22 basic EPS) vs net loss $42.5M in Q2 2023.","Cash, cash equivalents & marketable securities $354.5M as of June 30, 2024; runway into H1 2027.","Revenue from Chiesi collaboration: $88.8M license sale + $7.1M R&D services.","R&D expenses $35.1M (vs $36.3M); G&A expenses $8.7M (vs $10.0M).","PROSERA Phase 3 PAH trial enrollment ongoing; top-line results expected Q4 2025; Phase 3 PH-ILD trial to start mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":95842000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210145,"accession_number":"0001728117-24-000080","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gossamer Bio regains Nasdaq minimum bid price compliance; listing matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 18, 2024 confirming regained compliance with minimum bid price rule.","Previous non-compliance notice dated May 22, 2024; stock had failed to maintain $1.00 minimum bid for 30 consecutive days.","The minimum bid price deficiency is now resolved; Nasdaq has closed the matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228392,"accession_number":"0001728117-24-000069","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Gossamer Bio reports annual meeting results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Skye Drynan and John Quisel re-elected as Class II directors for three-year terms.","Ernst & Young LLP ratified as independent auditor for FY2024 with 189.7M for, 1.2M against.","Advisory vote on executive compensation approved with 116.0M for, 40.4M against, 5.8M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228391,"accession_number":"0001728117-24-000059","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Gossamer Bio receives Nasdaq minimum bid deficiency; cure period to Nov 18, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notice on May 22, 2024; stock below $1.00 for 30 consecutive business days through May 21.","Company has 180 calendar days, until November 18, 2024, to regain compliance.","To cure, closing bid must be at least $1.00 for ten consecutive business days.","If not cured, may transfer to Nasdaq Capital Market for additional 180 days or face delisting.","Company may consider a reverse stock split to address the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228390,"accession_number":"0001728117-24-000057","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio reports Q1 net loss $41.9M; announces Chiesi collaboration for seralutinib","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Chiesi collaboration provides $160M upfront; Gossamer and Chiesi split global development costs, profits in US.","Pro forma cash, cash equivalents and marketable securities $396M as of March 31, 2024.","PROSERA Phase 3 PAH study topline results expected Q4 2025; registrational Phase 3 PH-ILD to start mid-2025.","Net loss $41.9M ($0.19 per share) for Q1 2024 vs $49.2M ($0.52 per share) in Q1 2023.","R&D expenses $32.4M in Q1 2024 down from $37.8M YoY, primarily due to terminated programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228389,"accession_number":"0001728117-24-000052","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["1.01","1.02","3.02","8.01","9.01"],"status":"ready","headline":"Gossamer Bio enters global collaboration with Chiesi for seralutinib; receives $160M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Receives $160M development reimbursement; eligible for up to $146M regulatory and $180M sales milestones.","Gossamer leads US commercialization for PAH/PH-ILD with 50/50 profit split; Chiesi obtains ex-US rights with tiered royalties.","Companies plan to initiate Phase 3 registrational study of seralutinib in PH-ILD in mid-2025.","Existing MidCap credit facility terminated and repaid in full upon deal closing.","Chiesi receives equity option to purchase up to 9.9% of Gossamer at 107.5% of VWAP, min $1.63/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247098,"accession_number":"0001728117-24-000024","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Gossamer Bio appoints Dr. Nathan (PH-ILD expert) and biotech analyst Drynan to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Steven Nathan appointed as Class I director, effective March 11, 2024; brings pulmonary and PH-ILD expertise.","Skye Drynan appointed as Class III director; former Capital Group Partner and Senior BioPharma Analyst.","Each new director receives $40,000 annual cash retainer and option for 230,000 shares vesting over three years.","Dr. Nathan's guidance intended to support expansion of seralutinib clinical program into PH-ILD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247097,"accession_number":"0001728117-24-000018","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q4/FY23 results: first PAH patient dosed in Phase 3 PROSERA, cash $296M into H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First PAH patient dosed in registrational Phase 3 PROSERA study; topline results expected Q4 2025.","Japan PMDA accepted CTN, allowing inclusion of Japanese sites without PK bridging; could support Japanese NDA.","Cash, equivalents & marketable securities $296.4M at Dec 31, 2023; expected to fund operations into H1 2026.","Net loss for FY2023: $179.8M ($1.18 per share) vs $229.4M ($2.71) in FY2022.","R&D expenses FY2023: $135.3M vs $170.9M in FY2022; G&A: $38.5M vs $47.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247096,"accession_number":"0001728117-24-000013","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gossamer Bio regains Nasdaq minimum bid price compliance; deficiency closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on March 4, 2024 confirming compliance with minimum bid price rule.","Common stock had failed to maintain $1.00 bid price for 30 consecutive days as of Oct 2023.","Nasdaq listing qualification matter is now closed.","Compliance regained with Nasdaq Global Select Market listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264532,"accession_number":"0001728117-23-000157","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"John Quisel appointed to Gossamer Bio Board; brings PAH expertise from Acceleron/Merck","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Class III director, term expiring at 2024 annual meeting; joins Audit Committee.","Received option to purchase 230,000 shares vesting monthly over three years, plus $40,000 board retainer and $7,500 audit retainer annually.","Currently President & CEO of Disc Medicine; previously at Acceleron Pharma leading re-acquisition of sotatercept rights for PAH from Bristol-Myers Squibb.","Led initiative that culminated in Merck's $11B acquisition of Acceleron in 2021, highlighting deep PAH corporate development experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264531,"accession_number":"0001728117-23-000151","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Gossamer Bio adopts 2023 inducement plan reserving 6.76M shares for new hires and amends bylaws","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 2023 Inducement Plan with 6,762,279 common shares reserved for grants to new employees as material inducement to hire.","Plan substantially similar to 2019 Incentive Award Plan but no ISOs; adopted without stockholder approval per NASDAQ Rule 5635(c)(4).","Bylaws amended effective Nov 27, 2023 to address universal proxy rules under SEC Rule 14a-19 and enhance disclosure for stockholder nominations.","Amendments also include technical, modernizing and clarifying changes to the bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264530,"accession_number":"0001728117-23-000133","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q3 net loss $40M, cash sufficient into H1 2026; PROSERA study ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.0M ($0.21/share) vs $59.4M loss in Q3 2022; R&D expenses $31.2M (down from $44.5M).","Cash, equivalents & marketable securities $328.9M; expected to fund operations into first half of 2026.","Phase 3 PROSERA site activations ahead of schedule; first patient dosing expected in Q4 2023.","Additional TORREY open-label extension data (seralutinib in PAH) expected in Q4 2023.","FRI sub-study of TORREY presented at ERS 2023; evidence of improved pulmonary blood vessel volume."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264529,"accession_number":"0001728117-23-000129","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Gossamer Bio receives Nasdaq notice for non-compliance with $1.00 minimum bid price; 180-day cure period.","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Gossamer Bio on Oct 19, 2023 that its common stock had a closing bid price below $1.00 for 30 consecutive business days.","Company has until April 16, 2024 to regain compliance by maintaining at least $1.00 closing bid for 10 consecutive business days.","If not compliant by deadline, Gossamer may transfer to Nasdaq Capital Market for an additional 180-day cure period.","Company is evaluating options including a potential reverse stock split; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281768,"accession_number":"0001728117-23-000127","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gossamer Bio board member Kristina Burow resigns effective September 6, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kristina Burow resigned from the Board due to other board commitments, not due to any disagreement with the company.","Board size reduced from six to five directors; Class III directors reduced from two to one.","Resignation effective immediately on September 6, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281767,"accession_number":"0001728117-23-000107","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q2 net loss $42.5M; raises $212M in July private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.5M ($0.45/share) vs $56.5M ($0.74) in Q2 2022; R&D expenses decreased to $36.3M.","Cash, equivalents & marketable securities $162.1M as of June 30; pro forma for July placement total $374M.","Phase 3 PROSERA study of seralutinib in PAH expected to start in Q3 2023; primary endpoint 6MWD at week 24.","Additional TORREY open-label extension data expected in Q4 2023 or Q1 2024.","July private placement raised ~$212M gross from sale of shares and warrants to institutional investors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281766,"accession_number":"0001728117-23-000094","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Gossamer Bio raises $212M in private placement; discloses interim TORREY OLE data and PROSERA Phase 3 design","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 129.9M shares + warrants to purchase 32.5M shares at combined price $1.63125 per unit for gross proceeds ~$212M.","Warrants exercisable at $2.04/share, immediately exercisable, expire July 24, 2028.","Net proceeds to fund seralutinib development/commercialization and working capital.","Participation from NEA, EcoR1, Armistice, Farallon, Madison Avenue Partners, and others.","Interim TORREY OLE data and PROSERA Phase 3 design disclosed via separate 8-K; conference call July 25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281765,"accession_number":"0001728117-23-000091","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Gossamer Bio provides interim TORREY OLE data and PROSERA Phase 3 trial design","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Announced interim data from open-label extension of seralutinib in PAH patients.","Detailed design of planned Phase 3 PROSERA trial for seralutinib.","No specific efficacy or safety numbers disclosed in the filing or exhibit.","Corporate presentation furnished as Exhibit 99.1 contains the update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300734,"accession_number":"0001728117-23-000081","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Gossamer Bio shareholders approve officer liability amendment, re-elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to eliminate officer liability for monetary damages passed with 55.97M for, 2.92M against, effective June 8, 2023.","Directors Faheem Hasnain and Russell Cox re-elected as Class II directors for three-year terms.","Ernst & Young LLP ratified as independent auditor for FY 2023 with 76.28M for, 72,683 against.","Say-on-pay advisory vote on named executive officer compensation passed with 38.90M for, 19.98M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300733,"accession_number":"0001728117-23-000050","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q1 net loss $49.2M; advancing seralutinib to Phase 3 in PAH","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $49.2M ($0.52 per share) for Q1 2023 vs. $57.8M ($0.76) in Q1 2022.","Cash, equivalents and marketable securities of $201.9M as of March 31, 2023; expected to fund operations through at least 12 months.","Phase 3 registrational trial of seralutinib in PAH planned for 3Q23; FDA and EMA feedback on key design elements received.","Operational restructuring: headcount reduced by over 25%; all other clinical/preclinical programs terminated.","Initial open-label extension data from TORREY study expected mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300732,"accession_number":"0001728117-23-000030","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gossamer Bio discontinues GB5121 after FDA partial clinical hold; SAEs included fatal hemorrhage","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed partial clinical hold on all GB5121 trials after atrial fibrillation, sudden death, and fatal intracranial hemorrhage in STAR-CNS study.","Company terminated all ongoing GB5121 studies and discontinued development of the drug.","Enrollment had been paused March 17, 2023, based on benefit/risk and to prioritize seralutinib program.","No other pipeline updates disclosed; seralutinib remains the priority program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320675,"accession_number":"0001728117-23-000009","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio pauses GB5121 enrollment, advances seralutinib Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Seralutinib Phase 3 in PAH to start H2 2023; dose 90 mg BID, primary endpoint 6-minute walk distance.","TORREY open-label extension topline data expected mid-2023.","GB5121 Phase 1b/2 enrollment paused due to benefit/risk profile and resource prioritization toward seralutinib.","Cash of $255.7M at Dec 31, 2022; expected to fund operations into H2 2024.","Full-year 2022 net loss $229.4M ($2.71/share), vs $234.0M ($3.13/share) in 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338802,"accession_number":"0001728117-22-000102","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Gossamer Bio's Phase 2 TORREY study meets primary endpoint; seralutinib reduces PVR in PAH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 TORREY met primary endpoint: placebo-corrected PVR reduction of 96.1 dynes (14.3%, p=0.031).","Secondary endpoint 6MWD numerically favored seralutinib by 6.5 meters (not statistically significant).","In FC III patients: 21% PVR reduction (p=0.043) and 37m 6MWD improvement (p=0.048) vs placebo.","NT-proBNP reduced by 408.3 ng/L at Week 24 (p=0.0012); right heart structure/function improved.","Seralutinib well tolerated; cough most common TEAE (43% vs 38% placebo), no subdural hematomas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338801,"accession_number":"0001728117-22-000099","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q3 2022 net loss $59.4M; cash $304.4M; TORREY topline expected Nov/Dec","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $59.4M ($0.65/shr) vs $60.2M ($0.80/shr) in Q3 2021; cash $304.4M sufficient into Q2 2024.","R&D expenses $44.5M, G&A $11.5M for quarter ended Sep 30, 2022.","Phase 2 TORREY topline data for seralutinib expected in second half of Nov or first half of Dec 2022.","Enrollment ongoing in Phase 1b/2 STAR CNS study of GB5121 for relapsed/refractory CNS lymphomas.","Preclinical pipeline updates presented at multiple medical conferences; three internally developed programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356163,"accession_number":"0001728117-22-000084","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q2 net loss $56.5M; seralutinib Phase 2 readout on track for Nov/Dec 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $56.5M ($0.74/share) vs $59.8M ($0.80/share) in Q2 2021.","Cash, equivalents & marketable securities $222.2M as of June 30; pro forma $342M after $120M July 2022 private placement.","Seralutinib Phase 2 TORREY topline data expected second half November or first half December 2022.","GB5121 Phase 1b/2 STAR CNS study in PCNSL dosed first patient.","Commencing investment in registrational Phase 3 program for seralutinib targeted for Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356162,"accession_number":"0001728117-22-000057","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2022-07-13T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Gossamer Bio raises $120M via private placement of 16.6M shares at $7.21/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 16.6M shares at $7.21; gross proceeds ~$120M before expenses.","Participation by EcoR1 Capital, NEA, Weiss Asset Management, Rock Springs Capital, and others.","Proceeds to fund seralutinib R&D ahead of Phase 2 TORREY topline results in Q4 2022.","Expected close July 15, 2022; lock-up on shares until October 1, 2022.","Cash runway extended into mid-2024 with existing cash and debt facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374526,"accession_number":"0001728117-22-000049","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Gossamer Bio stockholders re-elect three Class I directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kristina Burow, Thomas Daniel, and Sandra Milligan re-elected as Class I directors with over 89% of votes cast (excluding broker non-votes).","Ratification of Ernst & Young as independent auditor for FY 2022 passed with 99.9% of votes cast (59.2M for, 60k against).","Advisory vote on named executive officer compensation approved with 99.3% of votes cast (46.1M for, 31.9k abstentions).","All three management proposals passed; broker non-votes were 12.8M for director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374525,"accession_number":"0001728117-22-000046","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio Q1 net loss $57.8M ($0.76/diluted); TORREY enrollment complete; cash $271.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 TORREY study (seralutinib in PAH) completed enrollment; topline data expected Q4 2022.","Cash, cash equivalents & marketable securities: $271.6M as of March 31, 2022; runway into first half 2024.","Net loss of $57.8M ($0.76 per share) vs $57.6M ($0.78) in Q1 2021; R&D $42.3M, G&A $12.0M.","GB5121 Phase 1b/2 STAR CNS study in PCNSL expected to initiate Q2 2022.","GB7208 Phase 1 in neuroinflammatory diseases planned for H1 2023, pending TORREY results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374524,"accession_number":"0001728117-22-000035","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2022-04-25T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Gossamer Bio Phase 2 SHIFT-UC trial of GB004 misses primary endpoint; study terminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial of GB004 in mild-to-moderate active UC failed primary endpoint at week 12 (15.4% QD, 22.5% BID vs. placebo 17.9%).","No meaningful differences on secondary endpoints; Gossamer terminates treat-through and open-label extension portions.","Preliminary cash, cash equivalents, and marketable securities ~$272M as of March 31, 2022 (unaudited).","Target enrollment of 80 patients reached in Phase 2 TORREY trial of seralutinib in PAH; topline results expected Q4 2022.","Anticipates initiation of Phase 1b/2 STAR CNS trial of GB5121 in primary CNS lymphoma in late Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393018,"accession_number":"0001728117-22-000018","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Bio reports FY2021 net loss of $234M; cash $325M; pipeline milestones set for 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2021 was $56.3M ($0.74/share); FY2021 net loss $234M ($3.13/share).","Cash, cash equivalents and marketable securities totaled $325.2M at year-end 2021; expected to fund into H2 2023.","GB004 Phase 2 SHIFT-UC topline data (mild-to-moderate UC) expected Q2 2022; treat-through week 36 data in Q4 2022.","Seralutinib (GB002) Phase 2 TORREY PAH study topline data expected H2 2022, subject to COVID-19 developments.","GB5121 IND active; global Phase 1b/2 trial for primary CNS lymphoma expected to initiate in H1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411490,"accession_number":"0001728117-21-000103","cik":1728117,"company_name":"Gossamer Bio, Inc.","ticker":"GOSS","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gossamer Q3 net loss $60.2M ($0.80/shr); PAH study topline delayed to H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $60.2M for Q3 2021 vs $57.8M prior year, R&D $43.2M, G&A $12.5M.","Cash, equivalents and securities $366M as of Sept 30, 2021; sufficient into H2 2023.","Phase 2 TORREY (PAH) topline results now expected H2 2022 due to COVID-19 delays.","Phase 2 SHIFT-UC (ulcerative colitis) completed enrollment; topline Q2, treat-through data Q4 2022.","GB5121 advanced to Phase 1 healthy volunteers; GB7208 (MS) Phase 1 expected H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49215806.63240018,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-08T23:59:59+00:00|411490"}